A four-hit mechanism is sufficient for meningioma development.

IF 3.2 2区 医学 Q2 CLINICAL NEUROLOGY
Alex Devarajan, Carina Seah, Jack Y Zhang, Vikram Vasan, Rui Feng, Emily K Chapman, Tomoyoshi Shigematsu, Joshua Bederson, Raj K Shrivastava
{"title":"A four-hit mechanism is sufficient for meningioma development.","authors":"Alex Devarajan, Carina Seah, Jack Y Zhang, Vikram Vasan, Rui Feng, Emily K Chapman, Tomoyoshi Shigematsu, Joshua Bederson, Raj K Shrivastava","doi":"10.1007/s11060-024-04877-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Meningiomas are central nervous system tumors whose incidence increases with age. Benign meningioma pathogenesis involves germline or somatic mutation of target genes, such as NF2, leading to clonal expansion. We used an established cancer epidemiology model to investigate the number of rate-limiting steps sufficient for benign meningioma development.</p><p><strong>Methods: </strong>Incidence data was obtained from the Surveillance, Epidemiology and End Results Program (SEER) for nonmalignant meningioma from 2004 to 2020. Age-adjusted incidence rates per 100,000 person-years were divided into 5-year bands. This was repeated for vestibular schwannomas as a negative control. The Armitage-Doll methodology was applied. Mathematical solutions correcting for volatile tumor microenvironments were applied to fit higher-order models using polynomial regression when appropriate. A 75:25 training:test split was utilized for validation.</p><p><strong>Results: </strong>222,509 cases of benign meningiomas were identified. We noted strong linear relationships between log-transformed incidence and age across the cohort and multiple subpopulations: male, white, black, Hispanic, Asian/Pacific Islander, and American Indian subpopulations all demonstrated R<sup>2</sup> = 0.99. Slopes were between 3.1 and 3.4, suggesting a four-step process for benign meningioma development. Female patients exhibited nonlinear deviations, but the corrected model demonstrated R<sup>2</sup> = 0.99 with a four-hit pathway. This model performed robustly on test data with R<sup>2</sup> = 0.99. Vestibular schwannomas demonstrated a slope of 2.1 with R<sup>2</sup> = 0.99, suggesting a separate three-step process.</p><p><strong>Conclusion: </strong>Four mutations are uniquely required for the development of benign meningiomas. Correcting for volatile tumor microenvironments reliably accounted for nonlinear deviations in behavior. Further studies are warranted to elucidate genomic findings suggestive of key mutations in this pathway.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-024-04877-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Meningiomas are central nervous system tumors whose incidence increases with age. Benign meningioma pathogenesis involves germline or somatic mutation of target genes, such as NF2, leading to clonal expansion. We used an established cancer epidemiology model to investigate the number of rate-limiting steps sufficient for benign meningioma development.

Methods: Incidence data was obtained from the Surveillance, Epidemiology and End Results Program (SEER) for nonmalignant meningioma from 2004 to 2020. Age-adjusted incidence rates per 100,000 person-years were divided into 5-year bands. This was repeated for vestibular schwannomas as a negative control. The Armitage-Doll methodology was applied. Mathematical solutions correcting for volatile tumor microenvironments were applied to fit higher-order models using polynomial regression when appropriate. A 75:25 training:test split was utilized for validation.

Results: 222,509 cases of benign meningiomas were identified. We noted strong linear relationships between log-transformed incidence and age across the cohort and multiple subpopulations: male, white, black, Hispanic, Asian/Pacific Islander, and American Indian subpopulations all demonstrated R2 = 0.99. Slopes were between 3.1 and 3.4, suggesting a four-step process for benign meningioma development. Female patients exhibited nonlinear deviations, but the corrected model demonstrated R2 = 0.99 with a four-hit pathway. This model performed robustly on test data with R2 = 0.99. Vestibular schwannomas demonstrated a slope of 2.1 with R2 = 0.99, suggesting a separate three-step process.

Conclusion: Four mutations are uniquely required for the development of benign meningiomas. Correcting for volatile tumor microenvironments reliably accounted for nonlinear deviations in behavior. Further studies are warranted to elucidate genomic findings suggestive of key mutations in this pathway.

四击机制足以导致脑膜瘤的发展。
目的:脑膜瘤是一种中枢神经系统肿瘤,发病率随年龄增长而增加。良性脑膜瘤的发病机制包括靶基因(如 NF2)的种系突变或体细胞突变,从而导致克隆扩增。我们利用已建立的癌症流行病学模型来研究良性脑膜瘤发病的限速步骤数量:我们从监测、流行病学和最终结果计划(SEER)中获得了 2004 年至 2020 年非恶性脑膜瘤的发病数据。每 10 万人年的年龄调整后发病率分为 5 年。作为阴性对照,前庭裂隙瘤的情况也是如此。采用了 Armitage-Doll 方法。在适当的情况下,采用多项式回归来拟合高阶模型,并应用数学解决方案对肿瘤微环境的波动进行校正。结果:共发现 222,509 例良性脑膜瘤。我们注意到,在整个群体和多个亚群中,对数转换后的发病率与年龄之间存在很强的线性关系:男性、白人、黑人、西班牙裔、亚洲/太平洋岛民和美洲印第安人亚群的 R2 均为 0.99。斜率介于 3.1 和 3.4 之间,表明良性脑膜瘤的发展过程分为四个步骤。女性患者表现出非线性偏差,但校正后的模型显示 R2 = 0.99,为四步路径。该模型在测试数据中表现稳健,R2 = 0.99。前庭裂隙瘤的斜率为 2.1,R2 = 0.99,表明这是一个单独的三步过程:结论:良性脑膜瘤的形成需要四种独特的突变。结论:良性脑膜瘤的发生需要四种突变,对肿瘤微环境的不稳定性进行校正可以可靠地解释非线性行为偏差。有必要开展进一步研究,以阐明提示该通路中关键突变的基因组发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信